The 340b Drug Pricing Program Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of The 340b Drug Pricing Program book. This book definitely worth reading, it is an incredibly well-written.
The 340B Drug Pricing Program by Felix C. Larsen Pdf
The 340B Drug Pricing Program (340B Program) and the Medicaid Drug Rebate Program require manufacturers to provide discounts on outpatient drugs in order to have their drugs covered by Medicaid. These discounts take the form of reduced sales prices for covered entities participating in the 340B Program--eligible hospitals and federal grantees--and rebates on drugs dispensed to Medicaid beneficiaries, shared by states and the federal government. This book looks at important issues pertaining to the 340B Drug Pricing Program.
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health
Author : United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health Publisher : Unknown Page : 112 pages File Size : 47,7 Mb Release : 2015 Category : Older people ISBN : STANFORD:36105050692859
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
Author : United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations Publisher : Unknown Page : 80 pages File Size : 52,8 Mb Release : 2006 Category : Medical ISBN : PSU:000058948880
Oversight and Administration of the 340B Drug Discount Program by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations Pdf
The Health Resources and Services Admin. (HRSA) oversees the 340B Drug Pricing Program, through which participating drug manufacturers give certain entities within the health care safety net -- known as covered entities (CE) -- access to discounted prices on outpatient drugs. CE include specified fed. grantees and hospitals. The number of CE sites has nearly doubled in the past 10 years to over 16,500. This study examines: (1) the extent to which CE generate 340B revenue, factors that affect revenue generation, and how they use the program; (2) how manufacturers' dist. of drugs at 340B prices affects CE or non-340B providers' access to drugs; and (3) HRSA's oversight of the 340B program. Charts and tables. A print on demand report.
Examining Oversight Reports on the 340B Drug Pricing Program by United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions Pdf
Prescription Drug Pricing: Background, Discount Programs and Cost Lowering Strategies by Elias B. Toft Pdf
Chapter 1 examines the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on the Federal and state budgets, and on American families. Chapter 2 addresses frequently asked questions about government and private-sector policies that affect drug prices and availability. Among the prescription drug topics covered are federally funded research and development, regulation of direct-to-consumer advertising, legal restrictions on reimportation, and federal price negotiation. The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs at discounted prices to covered entitiesâeligible clinics, hospitals, and othersâin order to have their drugs covered by Medicaid. Covered entities are only allowed to provide 340B drugs to certain eligible patients. Chapter 3 reviews the Health Resources and Services Administration's (HRSA) oversight of the 340B Program to ensure compliance with program rules. In 2017, nearly 60% of U.S. adults aged 18â64 reported being prescribed medication in the past 12 months. Approximately 70% of prescription medications carry out-of-pocket costs. Strategies to reduce prescription drug costs at the individual level are discussed in chapters 4 and 5. Each year, Americans pay more for prescription drugs, and rising drug prices have a disproportionate impact on older Americans. Chapter 6 examines the history of rising drug prices for the brand-name drugs most commonly prescribed for seniors. Generic drugsâcopies of brand-name drugsâlead to significant cost savings. Before a generic drug can be marketed, FDA must approve the generic drug application. According to FDA, applications go through an average of three cycles of review before being approved, which may take years. Chapter 7 examines 1) the first review cycle approval rate of generic drug applications in recent years and factors that may have contributed to whether applications were approved; and 2) changes FDA has made to increase the first review cycle approval rate.
Medicare Part B Drugs by United States Government Accountability Office Pdf
Approximately 40 percent of all U.S. hospitals participate in the 340B Drug Pricing Program, and the majority of 340B discounted drugs are sold to hospitals. Medicare reimburses hospitals for Part B drugs under a statutory formula regardless of the prices hospitals paid for the drugs. Stakeholders have questioned the increase in hospital participation in the 340B program, and the implications for Medicare and its beneficiaries, especially regarding cancer care; and whether certain of the program's hospital eligibility criteria target hospitals appropriately. GAO was asked to review hospitals' participation in the 340B and Medicare programs. This report (1) compares 340B hospitals with non-340B hospitals in terms of financial and other characteristics and (2) compares spending for Medicare Part B drugs at 340B hospitals, for all drugs and for oncology drugs, with spending at non-340B hospitals. To examine hospital participation using the most recent data available, GAO analyzed 2008 and 2012 data from HRSA and CMS to compare characteristics and Medicare Part B drug spending for 340B hospitals and non-340B hospitals.
Daniel R Levinson,Office of Inspector General (Oig),Us Department of Health and Human Servic
Author : Daniel R Levinson,Office of Inspector General (Oig),Us Department of Health and Human Servic Publisher : Scholar's Choice Page : 48 pages File Size : 49,9 Mb Release : 2015-02-16 Category : Electronic ISBN : 1297044665
Deficiencies in the Oversight of the 340b Drug Pricing Program - Scholar's Choice Edition by Daniel R Levinson,Office of Inspector General (Oig),Us Department of Health and Human Servic Pdf
This work has been selected by scholars as being culturally important, and is part of the knowledge base of civilization as we know it. This work was reproduced from the original artifact, and remains as true to the original work as possible. Therefore, you will see the original copyright references, library stamps (as most of these works have been housed in our most important libraries around the world), and other notations in the work. This work is in the public domain in the United States of America, and possibly other nations. Within the United States, you may freely copy and distribute this work, as no entity (individual or corporate) has a copyright on the body of the work.As a reproduction of a historical artifact, this work may contain missing or blurred pages, poor pictures, errant marks, etc. Scholars believe, and we concur, that this work is important enough to be preserved, reproduced, and made generally available to the public. We appreciate your support of the preservation process, and thank you for being an important part of keeping this knowledge alive and relevant.
Drug Pricing by U.s. Government Accountability Office Pdf
"Health Resources and ServicesAdministration (HRSA), within in theDepartment of Health and HumanServices (HHS), oversees the 340BDrug Pricing Program, through whichparticipating drug manufacturers givecertain entities within the health caresafety net-known as coveredentities-access to discounted priceson outpatient drugs. Covered entitiesinclude specified federal grantees andhospitals. The number of coveredentity sites has nearly doubled in thepast 10 years to over 16,500.The Patient Protection and AffordableCare Act (PPACA) mandated that GAOaddress questions related to the 340Bprogram. GAO examined: (1) theextent to which covered entitiesgenerate 340B revenue, factors thataffect revenue generation, and howthey use the program; (2) howmanufacturers' distribution of drugs at340B prices affects covered entities' ornon-340B providers' access to drugs;and (3) HRSA's oversight of the 340Bprogram. GAO reviewed key laws andguidance, analyzed relevant data, andconducted interviews with 61 340Bprogram stakeholders selected torepresent a range of perspectives,including HRSA, 29 covered entities,10 manufacturers and representatives,and 21 others. Selection ofstakeholders was judgmental and thus,responses are not generalizable. "
Untangle New Requirements and Strengthen Your 340B Drug Program The 340B Program Handbook: Integrating 340B into the Health-System Pharmacy Supply Chain The 340B Drug Program Handbook is the comprehensive guide for pharmacy leaders, hospital administrators, legal counsel, and pharmacy managers. Developed by Andrew L. Wilson, PharmD, FASHP, this practical, clear-cut reference provides the most up-to-date information needed to implement and keep a high-performing program running well, including: · Complying with 340B requirements · Maintaining technical supply chain efficiency · Meeting effectiveness goals · Achieving heath-system financial objectives
National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies Publisher : National Academies Press Page : 235 pages File Size : 51,8 Mb Release : 2018-03-01 Category : Medical ISBN : 9780309468084
Making Medicines Affordable by National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies Pdf
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Approximately 40% of all U.S. hospitals participate in the 340B Drug Pricing Program, and the majority of 340B discounted drugs are sold at hospitals. Medicare reimburses hospitals for Part B drugs under a statutory formula regardless of the prices hospitals paid for the drugs. Stakeholders have questioned the increase in hospital participation in the 340B program, and the implications for Medicare and its beneficiaries, especially regarding cancer care; and whether certain of the program's hospital eligibility criteria target hospitals appropriately. This report (1) compares 340B hospitals with non-340B hospitals in terms of financial and other characteristics; and (2) compares spending for Medicare Part B drugs at 340B hospitals. Tables and figures. This is a print on demand report.
